Corynebacterium striatum

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Corynebacterium striatum is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, club-shaped-shaped bacterium. It has been detected in at least 3 gut microbiome compilation studies or metastudies. The DNA G+C content is 57.6%. Corynebacterium striatum is probably a rare gut coloniser. (Coyle1993; Bernard2012Bergey)



  • This organism has been recovered from clinical sources (blood, wound, infection - CCUG) and human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. Is a known human pathogen. A possible gut commensal.
    • QUIRKS
  • Nonlipophilic.
    • GENERAL CHARACTERISTICS (Coyle1993); (Bernard2012Bergey);
    Character Response
  • Substrates hydrolysed or digested:
  • tyrosine;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; mannose; starch;
  • ±
  • Strain-dependent acid from carbs:
  • sucrose; glycerol;
  • Active enzymes:
  • Ala-Phe-Pro arylamidase; alkaline phosphatase; catalase; esterase lipase C8;
    • SPECIAL FEATURES (Coyle1993);
    Character Response
  • ✗
  • Metabolites not produced:
  • propionate; H₂S; indole;
  • ✗
  • VP test:
  • not active
  • Haemolysis:
  • variable
  • ✓
  • Nitrate:
  • reduced
  • ✗
  • NO3➔NO2:
  • not reduced
  • Pigments:
  • variable
    • RESPONSE TO ANTIBIOTICS (Goldstein2003); (Tyrrell2012); (Goldstein2008); (Goldstein2006a); (Goldstein2006b);
    Class Active Resistant
  • Penicillins:
  • ampicillin-sulbactam; doripenem; penicillin G;
  • penicillin;
  • Cephalosporins:
  • cefotetan; ceftazidime;
  • Macrolides:
  • quinupristin-dalfopristin;
  • azithromycin; clarithromycin; josamycin; roxithromycin;
  • Quinolines:
  • ciprofloxacin;
  • Polypep/ketides:
  • rifapentine;
  • Vancomycins:
  • vancomycin; dalbavancin; teicoplanin;
  • Miscellaneous antibiotics:
  • daptomycin; linezolid;
  • clindamycin; lincomycin;

  • Lagier, J.-C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.-F., Koonin, E. V., La Scola, B., & Raoult, D. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(12), 1185–1193.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Corynebacteriales Family:  Corynebacteriaceae Genus:  Corynebacterium Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Club rod Pigment:  variable
    Health:  Unknown
    Source:  clinical sources (blood, wound, infection - CCUG) and human faeces
    DNA G+C(%):  57.6
    		Aesculin:  neg Urea:  neg Gelatin:  neg Tyrosine:  + Hippurate:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg L-Arabinose:  neg Fructose:  + Galactose:  vr Glucose:  + Mannose:  + Rhamnose:  neg Ribose:  neg D-Tagatose:  neg Xylose:  neg Lactose:  neg Maltose:  neg Melezitose:  neg Sucrose:  d Trehalose:  vr Amygdalin:  neg Dextrin:  neg Glycogen:  neg Starch:  + D-Arabitol:  neg Glycerol:  d(neg) Inositol:  neg Mannitol:  neg Sorbitol:  neg Salicin:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Melibiose:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  + Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg β-Mannosidase:  neg ArgDH:  neg γ-Glu transf.:  neg LysDC:  neg OrnDC:  neg AlaPheProAA:  + LeuAA:  vr PyrrolidAA:  neg AlkalineP:  + AcidP:  vr Esterase(C4):  vr EstLip(C8):  + Lipase:  neg Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Propionate:  neg H2S:  neg Indole:  neg Pigment:  variable
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  Var(MIC50): >0.5, MIC90: >32, RNG: (0.03->32)
    ampicillin:  Var(MIC50): 0.5, MIC90: 4, RNG: (0.03-64)
    amp-sulb:  S(MIC50): 0.5, MIC90: 2, RNG: (0.015–2)
    penicillin:  R(MIC50): >8, MIC90: >8, RNG: (0.06–>8)
    penicillin_G:  S(MIC50): 0.5, MIC90: 2, RNG: (0.25-4)
    piper-taz:  Var(MIC50): 4, MIC90: 32, RNG: (<0.03->128)
    doripenem:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.015–0.25)
    ertapenem:  Var(MIC50): >0.5, MIC90: >16, RNG: (0.008->16)
    imipenem:  Var(MIC50): 0.04, MIC90: 32, RNG: (0.03–>32)
    meropenem:  Var(MIC50): 0.25, MIC90: >8, RNG: (0.06–>8)
    cefepime:  Var(MIC50): 1, MIC90: >32, RNG: (0.06–>32)
    cefotaxime:  Var(MIC50): 1, MIC90: >32, RNG: (0.03->32)
    cefotetan:  R(MIC50): >32, MIC90: >32, RNG: (2–>32)
    cefoxitin:  Var(MIC50): 8, MIC90: 64, RNG: (0.125–>128)
    ceftazidime:  R(MIC50): 32, MIC90: >64, RNG: (0.5–>64)
    azithromycin:  R(MIC50): >128, MIC90: >128, RNG: (0.03->128)
    erythromycin:  Var(MIC50): 4, MIC90: 16, RNG: (2->64)
    clarithromycin:  R(MIC50): >128, MIC90: >128, RNG: (0.015->128)
    quin-dalf:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.125-2)
    roxithromycin:  R(MIC50): >128, MIC90: >128, RNG: (0.015->128)
    telithromycin:  Var(MIC50): >0.12, MIC90: >16, RNG: (0.12->16)
    josamycin:  R(MIC50): >64, MIC90: >64, RNG: (16->64)
    linezolid:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.25-1)
    ciprofloxacin:  R(MIC50): >16, MIC90: >16, RNG: (0.5->16)
    levofloxacin:  Var(MIC50): 2, MIC90: 4, RNG: (0.12-64)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  Var(MIC50): 0.25-32), MIC90: Var(0.25-32
    dalbavancin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.015-1)
    teicoplanin:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.12-0.5)
    vancomycin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.125-0.5)
    rifapentine:  R(MIC50): >128, MIC90: >128, RNG: (0.015->128)
    clindamycin:  R(MIC50): >16, MIC90: >16, RNG: (0.12->16)
    lincomycin:  R(MIC50): >128, MIC90: >128, RNG: (0.25->128)
    daptomycin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.125-0.5)

    References

    SPECIFIC REFERENCES FOR CORYNEBACTERIUM STRIATUM
  • Goldstein2003 - In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates.
  • Coyle1993 - Pursuit of the Corynebacterium striatum Type Strain.
  • Bernard2012Bergey - Bergey's manual of systematic bacteriology. Vol. 5, The Actinobacteria. Part A & B. Corynebacteriaceae, Genus I. Corynebacterium
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Goldstein2008 - In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
  • Goldstein2006a - In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.
  • Goldstein2006b - In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CORYNEBACTERIUM STRIATUM
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • Added: April 08, 2021